Although oral corticosteroids are not recommended in stable chronic obstructive pulmonary disease (COPD), there is evidence of a subjective feeling of well-being among patients with COPD, a term often referred to as steroid euphoria.^[@bibr1-1479972317721929]^ This subjective benefit has however not shown to improve the maximal oxygen consumption (VO~2max~) in COPD patients.^[@bibr2-1479972317721929]^ One study confirmed the effect of corticosteroids in healthy individuals by administering 60 mg of prednisolone daily for 7 days, showing an increased time to exhaustion (TTE) at 70--75% of VO~2max~.^[@bibr3-1479972317721929]^ The mechanisms might be attributed to an impaired sensation of fatigue, reduced muscle inflammation after exercise or to increased availability of metabolic substrates during exercise (glucose and free fatty acids).^[@bibr4-1479972317721929]^ The aim of this study was to investigate whether 4 days of oral corticosteroids could preserve or increase exercise tolerance and muscle strength in stable COPD patients after performing a fatigue protocol.

The study was a randomized, double-blinded, parallel design with eight participants receiving 37.5 mg of prednisolone and six participants receiving placebo. Approval was obtained from local and national ethics committees (nos H-3-2012-142/ EudraCT 2012-004503-13). The study consisted of six visits: one baseline visit 5--7 days before five consecutive daily visits. At the baseline visit, eligibility was determined, and spirometry, body plethysmography, COPD Assessment Test (CAT), diffusion capacity (D~L~CO) and an incremental exercise test were performed. At visit 1, spirometry, CAT and maximal inspiratory/expiratory pressure (MIP/MEP) were assessed followed by a 5-minute warm up at 10% *W* ~max~ and 20 minutes at 40% *W* ~max~. A maximum voluntary contraction (MVC) of the quadriceps muscle on the participant's leading leg was then followed. After 5 minutes' recovery, participants performed a submaximal exercise test (SMET) at 70% *W* ~max~ according to ERS guidelines^[@bibr5-1479972317721929]^ to measure TTE. At visits 2, 3 and 4, participants performed a 5-minute warm up at 10% *W* ~max~ followed by two constant workload cycling tests at 40% *W* ~max~ of 20 minutes separated by 4 minutes' recovery. On visit 5, participants performed the same protocol as on visit 1. At visits 2, 3, 4 and 5, participants were instructed to take the investigated medicinal product 3 hours before the study visit ([Figure 1](#fig1-1479972317721929){ref-type="fig"}). For the statistical analysis, students *t*-tests and Mann--Whitney *U* tests were performed using SPSS (IBM, Version 19.0).
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Of the 16 screened patients, 14 were randomized and 2 were excluded. Baseline characteristics are presented in [Table 1](#table1-1479972317721929){ref-type="table"}. Nine patients were on LAMA, two on LABA, nine on LABA/ICS, nine on SABA, two on SAMA/SABA, one on ICS monotherapy, one on phosphodiesterase inhibitors and only one was a current smoker. No difference was found in TTE between the prednisolone and the placebo group *p* = 0.88 ([Table 2](#table2-1479972317721929){ref-type="table"}), however, both groups showed improvements in TTE from visit 1 to visit 5 (data not shown). For the secondary outcomes, there were no significant changes either except for MVC, which was significantly higher in the prednisolone group (*p* = 0.03).

###### 

Baseline characteristics of the included patients.
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  *N* = 14        Mean    SD
  --------------- ------- -------
  FEV~1~, l       1.02    0.46
  FEV~1~, %       30.55   12.8
  FVC, l          2.44    0.79
  FVC, %          56.71   15.29
  FEV~1~/FVC, %   41.49   11.8
  RV, l           4.96    1.37
  RV, %           201.8   61.7
  TLC, l          8.52    1.57
  TLC, %          119.4   22.1
  RV/TLC, %       57.4    8.3
  D~L~CO SB       4.43    1.48
  D~L~CO VA       0.89    0.30
  BMI             23.6    4.8
  Pack years      44      18.9
  CAT score       14      5.2
  Age             62.7    6.71
  VO~2max~        15.86   4.43
  *W* ~max~       75.0    27.6

SD: standard deviation; FEV~1~: forced expiratory volume in 1 second; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity; D~L~CO/VA: diffusing capacity of the lung for carbon monoxide/alveolar volume; BMI: body mass index; COPD: chronic obstructive pulmonary disease; CAT: COPD Assessment Test; SB: single breath; VO~2max~: maximal oxygen consumption; *W* ~max~: maximal work load at the incremental test.

###### 

Results of the primary and secondary outcomes after the study.
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  Delta values          Prednisolone *N* = 7      Placebo = 5            *p* Value
  --------------------- ------------------------- ---------------------- -----------
  FEV~1~, l             −0.01 \[0.03; −0.01\]     0.0 \[−0.5; 0.1\]      0.07
  FEV~1~, % predicted   −1.0 \[−2.0; 0.0\]        0.0 \[−1.5; 3.0\]      0.18
  FVC, l                −0.014 \[−0.21; −0.05\]   0.15 \[−1.0; 0.39\]    0.03^a^
  FVC, % predicted      −4.0 \[−4.0; −1.0\]       3.0 \[−2.5; 9.5\]      0.03^a^
  MIP                   −6.0 \[−20.0; −4.0\]      5.0 \[3.0; 9.5\]       0.054
  MEP                   4.0 \[−11.0; 20.0\]       −7.0 \[−10.0; −3.0\]   0.37
  CAT                   −2 \[−3.0; 1.0\]          −1.0 \[−2.0; 1.5\]     0.22
  BORG dyspnea          0 \[−1.0; 1.0\]           0.0 \[−1.5; 1.5\]      0.95
  BORG leg discomfort   1 \[0.0; 1.0\]            2.0 \[3.0; 9.5\]       0.83
  TTE                   51 \[−13; 110\]           13 \[−18; 208\]        0.88
  MVC                   5.15 \[3.35; 9.15\]       −2 \[−5.57; 3.95\]     0.03^a^

CI: confidence interval; FEV~1~: forced expiratory volume in 1 second; FVC: forced vital capacity; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; COPD: chronic obstructive pulmonary disease; CAT: COPD Assessment Test; TTE: time to exhaustion; MVC: maximal voluntary contraction.

^a^Significant difference between active and placebo group.

The observed improvement in the SMET in this study is probably due to familiarization with the procedure. Accordingly, the TTE on visit 5 might represent the participants' most accurate exercise tolerance. In previous studies using the SMET, the majority of participants had mild to moderate COPD,^[@bibr5-1479972317721929]^ whereas the patients in this study had very low lung function and were not accustomed to strenuous exercise. Although not powered, the MVC was significantly lower on visit 5 in the placebo group than in the prednisolone group, indicating an increase in muscle strength following the 3 days' cycling. This finding is in accordance with a previous study.^[@bibr6-1479972317721929]^ Future studies are warranted for evaluation of the effect of short-term systemic corticosteroid in cardiopulmonary measures of strenuous exercise in severe and very severe COPD.
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